On November 21, CVS Health fell 3.51% in After-Hours Trading, trading near $78.49 per share, with turnover of $44.87 million.
The move followed continued pressure on managed-care and health insurance names as investors digested a proposed expansion of Medicare Advantage audits, tighter scrutiny of insurer deductions, and renewed debate around Medicare-for-All.
Recent sector coverage showed CMS proposed widening Medicare Advantage audit scope and increasing review of deductions claimed by insurers, developments that triggered broad selling across health insurers. Earlier reports also noted CVS Health had already been facing investor caution around Medicare Advantage remediation and regulatory changes despite stronger third-quarter results, including adjusted EPS of $2.09 versus a $1.65 consensus estimate and full-year adjusted EPS guidance of at least $8.20.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)